← 返回

双硫仑/铜通过 ROS 诱导的 DNA 损伤触发 cGAS-STING 先天免疫通路,从而增强对 PD-1 检查点阻断的抗肿瘤反应

英文原题:Disulfiram/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade.

查看英文原题

Disulfiram/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade.

PubMed 2025/02/03(内容时间) Int J Biol Sci Q1 · IF 11.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫检查点阻断(ICBs)已成为治疗晚期恶性肿瘤的主要策略;然而,其临床疗效常受限于原发性或获得性耐药。利用先天免疫信号增加淋巴细胞向肿瘤的浸润,已被认为是增强ICBs抗癌免疫应答的一种有前景的方法。双硫仑(DSF)是一种FDA批准用于慢性酒精中毒的药物,已显示出强效抗肿瘤作用,尤其是与铜(Cu)联合使用时。

在此,我们证明DSF与Cu联合治疗(DSF/Cu)可强效激活癌细胞内在的cGAS-STING依赖性先天免疫信号通路。进一步研究显示,DSF/Cu通过诱导过量活性氧(ROS)生成,导致线粒体和核DNA损伤以及胞质dsDNA释放,从而触发先天免疫并增强抗肿瘤效应。

此外,DSF/Cu显著增加了CD8+细胞毒性淋巴细胞和自然杀伤(NK)细胞的瘤内浸润,并增强了PD-1检查点阻断在小鼠肿瘤模型中的治疗效果。

总体而言,我们的发现为DSF/Cu的抗癌和免疫调节功能提供了依据,并突出了重定位DSF以改善癌症患者对ICBs应答的潜力。

展开英文摘要原文

Immune checkpoint blockades (ICBs) have emerged as the leading strategy for treating advanced malignancies; however, their clinical efficacy is frequently constrained by primary or acquired resistance. Harnessing innate immune signaling to increase lymphocyte infiltration into tumors has been recognized a promising approach to augment the anti-cancer immune response to ICBs. Disulfiram (DSF), an FDA-approved drug for chronic alcoholism, has shown potent anti-tumor effect, particularly when used in combination with copper (Cu).

Here, we demonstrated a combination treatment of DSF and Cu (DSF/Cu) robustly activated cancer cell-intrinsic cGAS-STING-dependent innate immune signaling pathway.

Further studies revealed that DSF/Cu caused mitochondrial and nuclear DNA damage and the release of cytosolic dsDNA by inducing excessive reactive oxygen species (ROS) generation, thereby triggering innate immunity and enhancing anti-tumor effects.

Moreover, DSF/Cu significantly increased the intratumoral infiltration of CD8 + cytotoxic lymphocytes and natural killer (NK) cells, and potentiated the therapeutic efficacy of PD-1 checkpoint blockade in murine tumor models.

Overall, our findings provide a rationale underlying the anti-cancer and immunomodulatory function of DSF/Cu and highlight the potential of repurposing DSF to improve responses to ICBs in cancer patients.

论文信息

作者
Yuan M、Shi L、Liu Y、Xiang K、Zhang Y、Zhou Y、Wang J、Ji M
单位
Department of Endocrinology and International Joint Research Center for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.China
文献类型
非美国政府资助研究
期刊
International journal of biological sciences2025
原文标识
PubMed 39990655 · DOI 10.7150/ijbs.105575